DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

Information source: University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Mellitus

Intervention: GIP-infusion (Other); Sodium-chloride (Other); GLP-2 infusion (Other)

Phase: N/A

Status: Completed

Sponsored by: University Hospital, Gentofte, Copenhagen


The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.

Clinical Details

Official title: The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science

Primary outcome: plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Caucasians over 18 years with type 1 diabetes (WHO criteria)

- Arginine test without rise in plasma C-peptide

- Normal blood Hemoglobin

- Informed consent

Exclusion Criteria:

- Liver disease

- Diabetic nephropathy

- Treatment with medications unpausable for 12 hours

Locations and Contacts

University Hospital, Gentofte, Hellerup, Capital Region 2900, Denmark
Additional Information

Starting date: January 2008
Last updated: February 12, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017